{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 27,
  "pageCount": 58,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "market_landscape",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "bar_chart_horizontal",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/27",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-27",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Oncology is still going to be the most popular TA from the view of commercial attractiveness as huge unmet needs still exist for many of its indications.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-3cd0a31fd4e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.48,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Perspectives on popular therapeutic areas for new clinical trial in 2022-27* (N=101)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d069647-2144-4232-abc7-162cfbe8a97c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.03,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "Note: *Survey question: Which therapeutic areas do you think will be popular in terms of R&D in the next 5 years? (Please rate the level of agreement on a scale of 1 to 7...)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18124d69-de90-4078-8703-251b8cea4f05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Average score: 6.4",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-47688c490ac5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.21
      },
      "kind": "quote",
      "text": "Market feedback: Quotes from CEO, Founder, and R&D Lead regarding oncology, immunology, and rare diseases.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0de44e1-0dc2-46f2-a0ba-08c10c8ae9d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Oncology is still going to be the most popular TA from the view of commercial attractiveness as huge unmet needs still exist for many of its indications, especially those with low survival rate, which patients will spare all efforts to cure and pay. - CEO, a Chinese biopharma, Sept. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-409ffe3a2458",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.15,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: L.E.K. survey and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4c71452-5994-4f8c-a6a5-507ea46e35a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology, immunology & rheumatology, rare diseases and CNS are perceived of high commercial attractiveness by respondents in the next 5 years",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8cb84567-6134-4d7b-95e8-a3c1bd348452",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Increasing Focus of More Commercially Attractive Development Areas",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fa41739-4eda-4063-96a2-13f7ca05ebc5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Average score",
      "numberRaw": "6.4",
      "numberKind": "plain",
      "actionTitle": "Oncology, immunology & rheumatology, rare diseases and CNS are perceived of high commercial attractiveness by respondents in the next 5 years",
      "calloutText": "Oncology is still going to be the most popular TA from the view of commercial attractiveness as huge unmet needs still exist for many of its indications.",
      "numberScale": null,
      "numberValue": 6.4,
      "metricFamily": "index_score",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}